Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy

This episode features leading experts Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, and Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, who provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations. They explore treatment strategies at first relapse and for double-refractory patients, including fixed-duration combinations and the emerging role of the non-covalent BTK inhibitor, pirtobrutinib. Additionally, the experts share their perspectives on the role of allogeneic stem cell transplantation and CAR T-cell therapy, and offer a glimpse into promising therapies on the horizon, such as BTK degraders and bispecific antibodies.

The post Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy appeared first on VJHemOnc.